Stock search

Ticker or company name

VRTX card

VRTX price forecast

Vertex Pharmaceuticals$537,79

P/E now is 34,6. Average over 5 years: 27,6 (range 25–30). The stock is 25% above its history.

Base · FY2030

$673,74+5,6% a year

The base case gives 5,6% a year, below your target of 10%.

Settings

%

No analyst consensus: assumptions come from the company's last 5 years. Change any in the table.

Assumptions by year

FY2026FY2027FY2028FY2029FY2030
Revenue growth, %
Net margin, %
Change in shares, %
Payout ratio, %
P/E low
P/E base
P/E high
Revenue$13,7 bn$15,6 bn$17,8 bn$20,3 bn$23,2 bn
Net income$3,64 bn$4,15 bn$4,74 bn$5,41 bn$6,17 bn
EPS$14,16$16,23$18,59$21,30$24,41

Changed values are highlighted. Bear and bull cases: growth ∓ 5,6%, margin ∓ 2 pp, low and high P/E.

Price at year end

  • Base
  • Bear – Bull
  • now $537,79

The dot is the base case, the line runs from bear to bull, the dashed line is today's price.

Result at the end of FY2030

Bear$445,96

Price change
−17,1%
A year
−4,4%
Fair value today
$301,15
Margin of safety
−44,0%

Base$673,74

Price change
+25,3%
A year
+5,6%
Fair value today
$454,96
Margin of safety
−15,4%

Bull$1 001,81

Price change
+86,3%
A year
+16,3%
Fair value today
$676,50
Margin of safety
+25,8%

What growth the price implies

For the stock to return 10% a year, revenue must grow 18% a year to FY2030 at a 26,6% margin and P/E 27,6.

Growth over 5 years
14,1%
Analyst consensus
no data
In your model
14,1%

Calculated from your assumptions. Not an investment recommendation.

Base · FY2030$673,74+5,6% a year